JP2012522788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522788A5 JP2012522788A5 JP2012503632A JP2012503632A JP2012522788A5 JP 2012522788 A5 JP2012522788 A5 JP 2012522788A5 JP 2012503632 A JP2012503632 A JP 2012503632A JP 2012503632 A JP2012503632 A JP 2012503632A JP 2012522788 A5 JP2012522788 A5 JP 2012522788A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antibody
- antagonist
- disease
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013691 Interleukin-17 Human genes 0.000 claims 12
- 108050003558 Interleukin-17 Proteins 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16567709P | 2009-04-01 | 2009-04-01 | |
| US61/165,677 | 2009-04-01 | ||
| PCT/US2010/029280 WO2010114859A1 (en) | 2009-04-01 | 2010-03-30 | Treatment of insulin-resistant disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522788A JP2012522788A (ja) | 2012-09-27 |
| JP2012522788A5 true JP2012522788A5 (enExample) | 2013-05-16 |
| JP5795306B2 JP5795306B2 (ja) | 2015-10-14 |
Family
ID=42229822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503632A Active JP5795306B2 (ja) | 2009-04-01 | 2010-03-30 | インスリン抵抗性疾患の治療 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100266595A1 (enExample) |
| EP (1) | EP2413967A1 (enExample) |
| JP (1) | JP5795306B2 (enExample) |
| KR (1) | KR101766927B1 (enExample) |
| CN (1) | CN102448493B (enExample) |
| AR (1) | AR075998A1 (enExample) |
| AU (1) | AU2010232692C1 (enExample) |
| BR (1) | BRPI1011535A2 (enExample) |
| CA (1) | CA2752908A1 (enExample) |
| CL (1) | CL2011002416A1 (enExample) |
| CO (1) | CO6410313A2 (enExample) |
| CR (1) | CR20110552A (enExample) |
| EC (1) | ECSP11011429A (enExample) |
| IL (1) | IL214745A0 (enExample) |
| MA (1) | MA33248B1 (enExample) |
| MX (1) | MX347978B (enExample) |
| NZ (1) | NZ595005A (enExample) |
| PE (1) | PE20120628A1 (enExample) |
| RU (1) | RU2537142C2 (enExample) |
| SG (1) | SG174891A1 (enExample) |
| TW (1) | TWI474833B (enExample) |
| UA (1) | UA105384C2 (enExample) |
| WO (1) | WO2010114859A1 (enExample) |
| ZA (1) | ZA201106076B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482920B2 (en) * | 2002-02-12 | 2011-07-20 | Hunza di Pistolesi Elvira & C. S.a.S. | Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| EP3214442A1 (en) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a |
| US9117641B2 (en) | 2012-10-29 | 2015-08-25 | Perkinelmer Health Sciences, Inc. | Direct sample analysis device adapters and methods of using them |
| PT2950780T (pt) * | 2013-02-04 | 2020-07-07 | Sanofi Sa | Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina |
| TWI780236B (zh) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| JP6641280B2 (ja) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| KR102321861B1 (ko) | 2017-03-10 | 2021-11-05 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4783469A (en) | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| WO1990001038A1 (en) | 1988-07-20 | 1990-02-08 | Nordisk Gentofte A/S | Human insulin analogs and preparations containing them |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| CA2147180A1 (en) | 1992-10-15 | 1994-04-28 | Gokhan S. Hotamisligil | Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function |
| US5527307A (en) | 1994-04-01 | 1996-06-18 | Minimed Inc. | Implantable medication infusion pump with discharge side port |
| US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5939269A (en) | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5637095A (en) | 1995-01-13 | 1997-06-10 | Minimed Inc. | Medication infusion pump with flexible drive plunger |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| NZ314406A (en) | 1996-03-18 | 2000-12-22 | Sankyo Co | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6040292A (en) | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
| US6187333B1 (en) | 1999-09-20 | 2001-02-13 | Diabex, Inc. | Method for treating, controlling, and preventing diabetes mellitus |
| ES2333772T3 (es) | 1999-12-23 | 2010-03-01 | Genentech, Inc. | Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas. |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| CA2461818A1 (en) | 2001-10-15 | 2003-04-24 | Genentech, Inc. | Treatment and diagnosis of insulin resistant states |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| DE602005013805D1 (de) * | 2004-09-21 | 2009-05-20 | Merck Serono Sa Coinsins | Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen |
| DE602006009834D1 (de) * | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| AU2007352412B2 (en) * | 2007-04-27 | 2013-05-16 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| ES2465223T3 (es) * | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| EP2182943B1 (en) * | 2007-07-23 | 2016-10-26 | Janssen Biotech, Inc. | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
| WO2009043171A1 (en) * | 2007-10-02 | 2009-04-09 | Institut National De La Recherche Scientifique | Method of regulating the th17 pathway and its associated metabolic impact |
-
2010
- 2010-03-30 RU RU2011144122/15A patent/RU2537142C2/ru not_active IP Right Cessation
- 2010-03-30 SG SG2011068293A patent/SG174891A1/en unknown
- 2010-03-30 KR KR1020117025865A patent/KR101766927B1/ko not_active Expired - Fee Related
- 2010-03-30 CN CN201080023924.3A patent/CN102448493B/zh active Active
- 2010-03-30 AR ARP100101033A patent/AR075998A1/es not_active Application Discontinuation
- 2010-03-30 TW TW099109698A patent/TWI474833B/zh not_active IP Right Cessation
- 2010-03-30 US US12/749,876 patent/US20100266595A1/en not_active Abandoned
- 2010-03-30 JP JP2012503632A patent/JP5795306B2/ja active Active
- 2010-03-30 MA MA34316A patent/MA33248B1/fr unknown
- 2010-03-30 CA CA2752908A patent/CA2752908A1/en not_active Abandoned
- 2010-03-30 EP EP10712243A patent/EP2413967A1/en not_active Withdrawn
- 2010-03-30 UA UAA201112634A patent/UA105384C2/ru unknown
- 2010-03-30 MX MX2011010273A patent/MX347978B/es active IP Right Grant
- 2010-03-30 PE PE2011001691A patent/PE20120628A1/es not_active Application Discontinuation
- 2010-03-30 WO PCT/US2010/029280 patent/WO2010114859A1/en not_active Ceased
- 2010-03-30 BR BRPI1011535A patent/BRPI1011535A2/pt not_active IP Right Cessation
- 2010-03-30 AU AU2010232692A patent/AU2010232692C1/en not_active Ceased
- 2010-03-30 NZ NZ595005A patent/NZ595005A/en not_active IP Right Cessation
-
2011
- 2011-08-18 IL IL214745A patent/IL214745A0/en unknown
- 2011-08-18 ZA ZA2011/06076A patent/ZA201106076B/en unknown
- 2011-08-24 CO CO11108185A patent/CO6410313A2/es not_active Application Discontinuation
- 2011-09-30 CL CL2011002416A patent/CL2011002416A1/es unknown
- 2011-10-19 CR CR20110552A patent/CR20110552A/es unknown
- 2011-11-01 EC EC2011011429A patent/ECSP11011429A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011144122A (ru) | Лечение нарушений, связанных с инсулинорезистентностью | |
| JP2014502955A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| IL261019A (en) | Antibodies to 6 -il and their use | |
| NZ597915A (en) | Combination therapy for treatment of immune disorders | |
| JP2019531273A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| JP2009519257A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| JP2018534933A5 (enExample) | ||
| JP2014534239A5 (enExample) | ||
| JP2017079785A5 (enExample) | ||
| ES2871574T3 (es) | Combinación de anticuerpo anti CD19 con un inhibidor de BCL-2 y usos de la misma | |
| JP2009539841A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| IL180364A (en) | Use of antibodies specifically related to amyloid-beta peptide in the manufacture of drugs for the treatment of diseases characterized by amyloid-beta deficiency, pharmaceutical compositions including them and methods for their preparation and methods for use thereof | |
| JP2012046518A5 (enExample) | ||
| JP2010505850A5 (enExample) | ||
| JP2006506333A5 (enExample) | ||
| JP2010500360A5 (enExample) | ||
| WO2007147090A3 (en) | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity | |
| JP2014509662A5 (enExample) | ||
| JP2010500370A5 (enExample) |